Post test RTD 1/18/23

  A high-responding inhibitor is defined by a Bethesda assay value of

• ≥0.3 BU

• ≥0.5 BU

• ≥1.0 BU

• ≥5.0 BU

Chimeric bispecific antibody directed against enzyme FIXa and the zymogen FX

• FEIBA

• Recombinant Activated Factor VIIa (rFVIIa)

• Emicizumab

• Obizur

The pivotal clinical trials on the use of emicizumab in hemophilia A patients

Answer explanation

HAVEN

Proposed mechanism of action of Radiotherapy in the treatment of Pseudotumor

• Causing inflammation and fibrinogenesis

• Damage to DNA

• Blocking cell division

• Promotes granulation

Classified as life-threatening in Hemophilia EXCEPT:

• Intracranial

• Genitourinary

• Neck/throat

• Gastrointestinal

Treatment of choice for patients WITH inhibitors

• FFP and Cryoprecipitate

• Clotting Factor Concentrates

• Bypassing Agents

• Emicizumab

Works through decreasing vascularity of hypervascular lesions or regions thereby arresting hemorrhage

• Ionizing Radiation

• Embolization

• Ligation

• Electrocauterization